{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-036875","form_type":"8-K","ticker":"BCRX","cik":"0000882796","company_name":"BIOCRYST PHARMACEUTICALS INC","filed_at":"2025-10-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.457668+00:00","generated_at":"2026-05-17T05:11:14.669874+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioCryst completes sale of European ORLADEYO business; receives $250M upfront","bullets":["Received $250M cash from sale of European ORLADEYO assets to Neopharmed Gentili; up to $14M in milestones.","Transaction valued at ~5.4x trailing 12-month European ORLADEYO sales (through June 2025).","Will use proceeds to retire $199M Pharmakon term loan, strengthening balance sheet.","Reaffirms FY2025 revenue guidance of $580M–$600M, expects upper half excluding European revenue.","European business was approximately breakeven; divestiture improves operating margin and focuses on U.S. core."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-036875","json":"https://secwatch.observer/filing/0001140361-25-036875.json","markdown":"https://secwatch.observer/filing/0001140361-25-036875.md","text":"https://secwatch.observer/filing/0001140361-25-036875.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882796/000114036125036875/0001140361-25-036875-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882796/000114036125036875/ef20056247_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:11:14.669874+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}